Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

Liu, Xiaowei; Wang, Zheng; Zhao, Chan; Wang, Hanping; Guo, Xiaoxiao; Zhou, Jiaxin; Duan, Lian; Si, Xiaoyan; Li, Yue; Wang, Mengzhao; Zhang, Meifen; Zhang, Li

doi:10.1111/1759-7714.13327

Cited by 24 publications

(22 citation statements)

References 33 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although ocular irAEs are infrequent based on the previous study, they can cause a deterioration of the quality of life and exert an influence on the compliance of patients. Lots of studies have reported the ocular adverse events secondary to ICIs (19,25,26,30,31,153,(164)(165)(166)(167)(168) and the grade of the adverse events had been published recently based on Common Terminology Criteria for Adverse Events. While no study had reported the ocular irAEs in lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer

Zhou

Wei

2021

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are novel immunotherapy-based drugs that have become increasingly popular in the treatment of lung cancer. Researchers have recognized ocular immune-related adverse events (irAEs) secondary to ICIs because of their vision-threatening characteristics. However, they are incompletely characterized and no studies have reported the ICI-related ocular irAEs in lung cancer. Therefore, we aimed to comprehensively illustrate the clinical characteristics, contributory factors, diagnosis, and management of ICI-related ocular irAEs in lung cancer, based on previously reported 79 patients. Ophthalmoplegia (40.51%), uveitis (20.25%), and dry eye (17.72%) were the most common ICI-related ocular irAEs in lung cancer. Ptosis was the most common (36.71%) and the highest mortality (23.33%) of ophthalmoplegia. Patients in Asia and patients who underwent combination therapy with programmed cell death-1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors demonstrated significantly higher frequency of ophthalmoplegia than other ocular irAEs. Most ICI-related ophthalmoplegia and uveitis in lung cancer were observed in the first 10 weeks following the initiation of ICIs. Furthermore, the onset time of dry eye and other ocular irAEs was much longer. In addition, 92.31% of the patients with ocular irAEs other than ophthalmoplegia could be remised. In conclusion, ocular irAEs secondary to ICIs in lung cancer are non-negligible, particularly ophthalmoplegia. Ethnicity and the type of ICIs play important roles in the distribution of ocular irAEs. ICI-related ophthalmoplegia in lung cancer presented with early onset and worse prognosis features, thus necessitating further attention.

show abstract

Section: Discussionmentioning

confidence: 99%

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer

Zhou

Wei

2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Aufgrund der Kombination aus granulomatöser Uveitis, schwerer Chorioiditis mit Aderhautamotio, exsudativer Ablatio retinae und exsudativer Makulopathie gehen wir auch bei unserem Patienten von einer bilateralen Vogt-Koyanagi-Haradaartigen Uveitis aus. Diese kann als Nebenwirkung von Immun-Checkpoint-Inhibitoren nur einzelne Komponenten des Vogt-Koyanagi-Harada-Syndroms aufweisen [8]. Die Uveitis war unter systemischer Kortikosteroidtherapie rückläufig.…”

Section: Verlaufunclassified

Beidseitige Nivolumab-assoziierte Vogt-Koyanagi-Harada-artige Uveitis bei einem Patienten mit metastasiertem Nierenzellkarzinom

Czichos

Wawrzynów

Chamalis

et al. 2021

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

Mit dem vermehrten Einsatz von Immun-Checkpoint-Inhibitoren in der Behandlung verschiedener, häufig bisher nicht therapierbarer Tumorerkrankungen treten immer häufiger autoimmune Nebenwirkungen auf. Hierzu zählt auch die Uveitis. Die medikamenteninduzierte Uveitis stellt somit ein seltenes, jedoch zunehmend auftretendes Krankheitsbild dar. ▶ Abb. 1 (a = rechts, b = links): Spaltlampenfotografie des Glaskörpers. Es finden sich beidseits Entzündungszellen und "snow balls".

show abstract

“…Such adverse events may be more severe than their spontaneously occurring counterparts and they may run a different clinical course . Checkpoint‐induced myasthenia gravis has been shown to be lethal in one‐third of all cases ; anti‐acetylcholine antibodies are usually not detectable. Patients and their families should be informed about this type of adverse events, especially given the fact that neurological symptoms may be lethal if detected too late or not at all .…”

Section: Organ‐specific Adverse Events During Immune Checkpoint Blockadementioning

confidence: 99%

Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

Kähler¹,

Hassel

Heinzerling³

et al. 2020

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary CTLA‐4 and PD‐1 play a key role in tumor‐induced downregulation of lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the immune response to various cancer types. Anti‐CTLA‐4 and anti‐PD‐1 antibodies affect the interaction between tumor, antigen‐presenting cells and T lymphocytes. Clinical studies of the anti‐CTLA‐4 antibody ipilimumab and the anti‐PD‐1 antibodies nivolumab and pembrolizumab have provided evidence of their positive effects on overall survival in melanoma patients. Combined treatment using ipilimumab and nivolumab has been shown to achieve five‐year survival rates of 52 %. Such enhancement of the immune response is inevitably associated with adverse events. Knowledge of the spectrum of side effects is essential, both in terms of prevention and management. Adverse events include colitis, dermatitis, hypophysitis, thyroiditis, hepatitis and other, less common autoimmune phenomena. In recent years, considerable progress has been made in the detection and treatment of the aforementioned immune‐related adverse events. However, early diagnosis of rare neurological or cardiac side effects, which may be associated with increased mortality, frequently pose a challenge. The present update highlights our current understanding as well as new insights into the spectrum of side effects associated with checkpoint inhibitors and their management.

show abstract

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

Cited by 24 publications

References 33 publications

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer

Beidseitige Nivolumab-assoziierte Vogt-Koyanagi-Harada-artige Uveitis bei einem Patienten mit metastasiertem Nierenzellkarzinom

Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

Contact Info

Product

Resources

About